ClinicalTrials.gg
RecruitingNCT07044687Updated Sep 11, 2026

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

A Phase 4 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia, sponsored by AbbVie. Recruiting at 14 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Planned enrollment
71st of 202
100 · median 57
Started
2025
with 21 others
Phase 4
5 of 202
3 open now
Primary completion
2027-11
later than 76 of 143 live
Registered
169th of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 71st largest by planned enrollment, is one of 22 that started in 2025, is one of 5 in phase 4, reaches primary completion later than 76 of the 143 other live ones, and was the 169th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

110 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India.

The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing doses of venetoclax. Around 40 adult participants with a diagnosis of AML will be enrolled in the study at approximately 15 sites in India.

Participants will receive venetoclax oral tablets once daily in increasing doses until the study dose is achieved. Then ventoclax oral tablets will continue once daily thereafter. Azacitidine will be given by subcutaneous (SC) or intravenous (IV) injection on Days 1-7 of each cycle. The total study duration is approximately 29 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • AML
  • Venetoclax
  • Venclexta
  • Azacitidine
  • Treatment Naïve AML
  • Untreated AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation of acute myeloid leukemia (AML) diagnosis by 2016 World Health Organization (WHO) criteria, previously untreated, and ineligible for treatment with intensive chemotherapy.
  • (ECOG) performance status of:

    • 0 to 2 for subject ≥ 75 years of age.
    • 0 to 3 for subject ≥ 18 to 74 years of age.

Exclusion criteria

Exclusion Criteria:

  • History of any within 2 years prior to study entry with exception to those noted in the protocol.
  • Have received any drug 30 days prior to the first dose of study drug and have received strong inducers within 7 days prior to the initiation of study treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Venetoclax in Combination with Azacitidine

    Participants will receive venetoclax once daily in increasing doses until the study dose is achieved. Then ventoclaxwill continue once daily thereafter. Participants will receive azacitidine on Day 1-7 of each cycle. The total study duration is approximately 29 months.

    Drug: Venetoclax · Drug: Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Treatment Emergent Adverse Events (TEAE)s

    TEAEs defined as any adverse event (AE) with the onset after the first dose of study drug until 30 days after the last dose of the study drug.

    Time frame: Up to Approximately 29 Months

  2. Percentage of Participants with Post-Baseline Laboratory Abnormalities

    Laboratory abnormalities are defined based on the shifts from baseline to postbaseline laboratory values will be summarized using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: Up to Approximately 29 Months

Secondary outcomes

  1. Composite Complete Remission (CRc)

    (CRc) is defined as Complete remission (CR) or complete remission with incomplete marrow recovery (CRi) per the modified International Working Group (IWG) response criteria for AML in participants who received venetoclax and azacitidine combination study treatment.

    Time frame: Up to Approximately 29 Months

  2. Composite Complete Remission (CRc) by initiation of Cycle 2

    (CRc) is defined as Complete remission (CR) or complete remission with incomplete marrow recovery (CRi) per the modified International Working Group (IWG) response criteria for AML in participants who received venetoclax and azacitidine combination study treatment.

    Time frame: Up to Approximately 1 Month

  3. Complete Remission

    CR is defined as the modified IWG response criteria for AML in participants who received venetoclax and azacitidine combination study treatment.

    Time frame: Up to Approximately 29 Months

  4. Overall Survival (OS)

    OS is defined as the time measured from randomization until death from any cause.

    Time frame: Up to Approximately 29 Months

07

Study locations

11 of 14 sites recruiting
  • Fortis Memorial Research Institute /ID# 268697
    Gurgaon, Haryana 122002, India
    Completed

    Not enrolling at this site.

  • Healthcare Global Enterprises Limited (HCGEL) /ID# 272071
    Bengaluru, Karnataka 560027, India
    Completed

    Not enrolling at this site.

  • Mazumdar Shaw Medical Center /ID# 270677
    Bengaluru, Karnataka 560099, India
    Recruiting
  • Regional Cancer Centre /ID# 268785
    Thiruvananthapuram, Kerala 695011, India
    Recruiting
  • Tata Memorial Hospital - Mumbai /ID# 269177
    Mumbai, Maharashtra 400012, India
    Recruiting
  • LMMF's Deenanath Mangeshkar Hospital & Research Center /ID# 268781
    Pune, Maharashtra 411004, India
    Recruiting
  • Sahyadri Super Speciality Hospital /ID# 272074
    Pune, Maharashtra 411044, India
    Recruiting
  • All India Institute Of Medical Sciences - New Delhi /ID# 268357
    New Delhi, National Capital Territory of Delhi 110029, India
    Recruiting
  • Rajiv Gandhi Cancer Institute And Research Centre /ID# 268293
    New Delhi, National Capital Territory of Delhi 110085, India
    Completed

    Not enrolling at this site.

  • All India Institute Of Medical Sciences - Bhubaneswar /ID# 274879
    Bhubaneswar, Odisha 751019, India
    Recruiting
  • Apollo Cancer Centre /ID# 268780
    Chennai, Tamil Nadu 600035, India
    Recruiting
  • Cancer Institute (Wia) /ID# 268695
    Chennai, Tamil Nadu 600036, India
    Recruiting
  • Christian Medical College Vellore /ID# 279587
    Vellore, Tamil Nadu 632004, India
    Recruiting
  • Basavatarakam Indo American Cancer Hospital & Research Institute /ID# 268692
    Hyderabad, Telangana 500034, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 1, 2025
StartActual
Jul 24, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07044687
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Jul 24, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine

Start the discussion